Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694641 | 0.98 | LIPE (0.44) | LIPECTSKL3MBTL1CTSLCTSB | |
| SCHEMBL7365934 | 0.98 | LIPE (0.44) | LIPECTSKL3MBTL1CTSLCTSB | |
| SCHEMBL1576452 | 0.96 | CTSK (0.40) | LIPECTSKL3MBTL1CTSLCTSB | |
| SCHEMBL28702168 | 0.87 | USP2 (0.39) | LIPECTSKL3MBTL1CTSLCTSB | |
| SCHEMBL1430236 | 0.84 | LIPE (0.36) | LIPECTSKL3MBTL1CTSLCTSB | |
| SCHEMBL7151133 | 0.84 | GNAI3 (0.38) | LIPECTSKL3MBTL1CTSLCTSB | |
| SCHEMBL27760998 | 0.83 | EPHX1 (0.38) | LIPECTSKL3MBTL1CTSLCTSB | |
| SCHEMBL5651167 | 0.83 | LIPE (0.39) | LIPECTSKL3MBTL1CTSLCTSB | |
| SCHEMBL28942305 | 0.83 | EPHX1 (0.41) | LIPECTSKL3MBTL1CTSLCTSB | |
| SCHEMBL853648 | 0.82 | GNAI3 (0.41) | LIPECTSKCA1CA2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015104602-A2 | A PROCESS FOR THE PREPARATION OF ANAGLIPTIN AND ITS INTERMEDIATES THEREOF | WOCKHARDT LIMITED (IN) | 2015-07-16 | — | — | WO | claimed |
| CN-118459425-B | Preparation method of pyrrolidine-1-amine-dihydrochloride | 南通华祥医药科技有限公司 | 2025-11-14 | — | — | CN | disclosed |
| CN-119930589-A | Tricyclic compound, pharmaceutical composition and application | 广州国家实验室 | 2025-05-06 | — | — | CN | disclosed |
| CN-118459425-A | Preparation method of pyrrolidine-1-amine-dihydrochloride | 南通华祥医药科技有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118459425-A | Preparation method of pyrrolidine-1-amine-dihydrochloride | 南通华祥医药科技有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-116903628-A | FGFR2 inhibitors and methods of use | 深圳福沃药业有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| EP-0757675-A1 | NOVEL QUINOLONE 5-(N-HETEROSUBSTITUTED AMINO) ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996039384-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL)-GLYCINAMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| CN-1137273-A | Quinolizinone type compounds | ABBOTT LAB (US) | 1996-12-04 | — | — | CN | disclosed |
| WO-1995029894-A1 | NOVEL QUINOLONE 5-(N-HETEROSUBSTITUTED AMINO) ANTIMICROBIALS | THE PROCTER & GAMBLE COMPANY (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0666853-A1 | ANTIMICROBIAL 5-HYDRAZINO-QUINOLONE DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994010163-A1 | ANTIMICROBIAL 5-HYDRAZINO-QUINOLONE DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0341493-A2 | Optically active pyridonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1989-11-15 | — | — | EP | disclosed |
| EP-0310854-A1 | Process for the manufacture of 3-amino-1-benzyl-pyrrolidines | BAYER AG (DE) | 1989-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | LIPE 4425/4885CTSK 992/4885L3MBTL1 3057/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | LIPE 4425/4885CTSK 2690/4885L3MBTL1 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.